Inflammatory cytokine gene variants in coronary artery disease patients in Greece

Coronary Artery Disease

Volumn 19, Issue 8, 2008, Pages 575-582

  Manginas, Athanassios ^a,b   Tsiavou, Anastasia ^a   Chaidaroglou, Antigoni ^a   Giamouzis, Grigorios ^a   Degiannis, Dimitrios ^a   Panagiotakos, Demosthenis ^a   Cokkinos, Dennis V ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Coronary artery disease; Cytokine gene polymorphisms; IL 6, myocardial infarction

Indexed keywords

DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; CORONARY ARTERY DISEASE; CYTOKINES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREECE; HAPLOTYPES; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56849095125     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32831286e8     Document Type: Article

References (58)

1. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Eng J Med 2001; 343:1139-1147.
2. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53:31-47.
3. Hanson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
4. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
5. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007; 18:492-499.
6. Mori T, Sasaki J, Kawaguchi H, Handa K, Takada Y, Matsunaga A, et al. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995; 129:234-238.
7. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100:793-798.
8. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21:1574-1583.
9. Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older patients. Cardiovasc Res 2005; 66:265-275.
10. Stephens JW, Humphries SE. The molecular genetics of cardiovascular disease: clinical implications. J Intern Med 2003; 253:120-127.
11. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodelling. Circ Res 2004; 94:1543-1553.
12. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153.
13. Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006; 98:14-18.
14. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 1997; 34:404-410.
15. Tziakas DN, Chalikias GK, Hatzinikolaou HI, Parissis JT, Papadopoulos ED, Trypsianis GA, et al. Anti-inflammatory cytokine profile in acute coronary syndromes: behaviour of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. Int J Cardiol 2003; 92:169-175.
16. Wojakowski W, Maslankiewicz K, Ochala A, Wyderka R, Zuk-Popiolek I, Flak Z, et al. The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. Int J Mol Med 2004; 14:317-322.
17. Seljeflot I, Hurlen M, Solheim S, Arnesen H. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost 2004; 2:350-352.
18. Okopien B, Haberka M, Cwalina L, Kowalski J, Belowski D, Madej A, et al. Plasma cytokines as predictors of coronary heart disease. Res Commun Mol Pathol Pharmacol 2002; 112:5-15.
19. Pasqui AL, Di Renzo M, Bova G, Maffei S, Pompella G, Auteri A, et al. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med 2006; 6:38-44.
20. Kaur K, Sharma AK, Singal PK. Significance of changes in TNF-α and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 291:106-113.
21. Hutchinson JV, Pravica V, Sinnot PJ. Genetic regulation of cytokine synthesis: consequences for acute and chronic organ allograft rejection. Graft 1998; 1:15-21.
22. Bidwell J, Keen L, Gallacher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: online databases. Genes Immunity 1999; 1:3-19.
23. Topol EJ, Smith J, Plow EF, Wang QK. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 2006; 15:117-123.
24. Olivieri F, Antonicelli R, Cardelli M, Marchegiani F, Cavallone L, Mocchegiani E, et al. Genetic polymorphisms of inflammatory cytokines and myocardial infarction in the elderly. Mech Ageing Dev 2006; 127:552-559.
25. Wilson AG, Symon JA, McDowell T, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94:3195-3199.
26. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene. Eur J lmmunogenet 1997; 24:1-8.
27. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66:1014-1020.
28. Real JMF, Vendrell J, Richart C, Gutierrez C, Wifredo R. Platelet account and interleukin-6 gene polymorphism in healthy subjects. BMC Med Genet 2001; 2:6-11.
29. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-α gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-α gene. Hum Immunol 2000; 61:863-866.
30. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
31. Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001; 31:2357-2361.
32. Olivieri F, Bonafe M, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M, et al. The 174 G > C locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol 2002; 37:309-314.
33. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or non invasive strategy. JAMA 2001; 286:2107-2113.
34. Nawroth PP, Handley D, Stern DM. The multiple levels of endothelial cell coagulation factor interactions. Clin Haematol 1986; 151:293-321.
35. Dalmon J, Laurent M, Courtois G. The human â fibrinogen promoter contains a hepatocyte nuclear factor 1- dependent interleukin-6-responsive element. Mol and Cell Biol 1993; 13:1183-1193.
36. Nelken N, Coughlin S, Gordon D, Wilcox J. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88:1121-1127.
37. Stouthard J, Levi M, Hack C, Veenhof C, Romijn H, Sauerwein H, et al. Interleulin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-742.
38. Li ZY, Howarth SP, Tang T, Gillard JH. How critical is fibrous cap thickness to carotid plaque stability? A flow-plaque interaction model. Stroke 2006; 37:1195-1199.
39. Georges JL, Loukaci V, Poirier O, Evans A, Luc G, Arveiler D, et al. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Mol Med 2001; 79:300-305.
40. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22:2243-2252.
41. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103:2260-2265.
42. Licastro F, Chiappelli M, Caldarera CM, Tampieri C, Nanni S, Gallina M, et al. The concomitant presence of polymorphic alleles of interleukin-1beta, interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly men. Results from a pilot study. Mech Ageing Dev 2004; 125:575-579.
43. Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, et al. Relation of the 174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001; 88:1125-1128.
44. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
45. Nauck M, Winkelmann BR, Hoffmann MM, Bohm BO, Wieland H, Marz W. The interleukin-6 G(174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. Mol Med 2002; 80:507-513.
46. Bennermo M, Held C, Green F, Strandberg LE, Ericsson CG, Hansson LO, et al. Prognostic value of plasma interleukin-6 concentrations and the 174 G > C and 572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004; 174:157-163.
47. Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet 2004; 31:207-213.
48. Lieb W, Pavlik R, Erdmann J, Mayer B, Holmer SR, Fischer M, et al. No association of interleukin-6 gene polymorphism (174 G/C) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol 2004; 97:205-212.
49. Sie MP, Sayed-Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HA, Hofman A, et al. Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 2006; 26:212-217.
50. Antonicelli R, Olivieri F, Cavallone L, Spazzafumo L, Bonafè M, Marchegiani F, et al. Tumor necrosis factor-alpha gene 308 G > A polymorphism is associated with ST-Elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis 2005; 16:489-493.
51. Antonicelli R, Olivieri F, Bonafè M, Cavallone L, Spazzafumo L, Marchegiani F, et al. The interleukin-6 174 G > C promoter polymorphism is associated with an higher nsk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005; 103:266-271.
52. Giacconi R, Cipriano C, Albanese F, Boccoli G, Saba V, Olivieri F, et al. The 174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing. Exp Gerontol 2004; 39:621-628.
53. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000; 908:244-254.
54. Kelberman D, Hawe E, Luong LA, Mohamed-Ali V, Lundman P, Tornvall P, et al.; HIFMECH Study Group. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost 2004; 92:1122-1128.
55. Biasucci LM, Liuzzo G, Button A, Maseri A. The variable role of inflammation in acute coronary syndromes and in restenosis. Semin Interv Cardiol 1999; 4:105-110.
56. Frostegérd J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th 1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33-43.
57. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, et al. Interfeukin-6 gene 174 G> C and 572 G> C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21:1458-1463.
58. Bennet A, Prince J, Fei GZ, Lyrenäs L, Huang Y, Wiman B, et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003; 171:359-367.